Mark T Madsen1, Yusuf Menda1, Thomas M O'Dorisio2, M Sue O'Dorisio3. 1. Department of Radiology, University of Iowa, Iowa City, IA, 52242, USA. 2. Department of Endocrinology, University of Iowa, Iowa City, IA, 52242, USA. 3. Department of Pediatrics, University of Iowa, Iowa City, IA, 52242, USA.
Abstract
OBJECTIVE: Although personalized dosimetry may be desirable for radionuclide therapy treatments, the multiple time samples required to determine the total integrated activity puts a burden on patients and clinic resources. The aim of this paper is to demonstrate that when some prior knowledge is known about the tracer kinetic parameters, the total integrated activity (and thus radiation dose) can be estimated from a single time sample. METHODS: Mathematical derivations have been performed to generate equations for the total integrated activity in terms of a single time sample of activity for monoexponential and biexponential clearance. Simulations were performed using both exponential models where the rate constants and associated parameters were randomly sampled from distributions with a known mean. The actual total integrated activity for each random sample was compared with the estimated total integrated activity using the mean value of the parameters. Retrospective analysis of 90 Y DOTATOC data from a clinical trial provided a comparison of actual kidney dose with the estimated kidney dose using the single time point approach. RESULTS: The optimal sampling time for the single point approach was found to be equal to the mean time of the rate constant. The simulation results for the monoexponential and biexpoential models were similar. Regressions comparing the actual and estimated total integrated activity had very high correlations (r2 > 0.95) along with acceptable standard errors of estimate, especially at the optimal sampling point. The retrospective analysis of the 90 Y DOTATOC data also yielded similar results with an r2 = 0.95 and a standard error of estimate of 61 cGy. CONCLUSIONS: In situations where there is prior knowledge about the population averages of kinetic parameters, these results suggest that the single time point approach can be used to estimate the total integrated activity and dose with sufficient accuracy to manage radionuclide therapy. This will make personalized dosimetry much easier to perform and more available to the community.
OBJECTIVE: Although personalized dosimetry may be desirable for radionuclide therapy treatments, the multiple time samples required to determine the total integrated activity puts a burden on patients and clinic resources. The aim of this paper is to demonstrate that when some prior knowledge is known about the tracer kinetic parameters, the total integrated activity (and thus radiation dose) can be estimated from a single time sample. METHODS: Mathematical derivations have been performed to generate equations for the total integrated activity in terms of a single time sample of activity for monoexponential and biexponential clearance. Simulations were performed using both exponential models where the rate constants and associated parameters were randomly sampled from distributions with a known mean. The actual total integrated activity for each random sample was compared with the estimated total integrated activity using the mean value of the parameters. Retrospective analysis of 90 Y DOTATOC data from a clinical trial provided a comparison of actual kidney dose with the estimated kidney dose using the single time point approach. RESULTS: The optimal sampling time for the single point approach was found to be equal to the mean time of the rate constant. The simulation results for the monoexponential and biexpoential models were similar. Regressions comparing the actual and estimated total integrated activity had very high correlations (r2 > 0.95) along with acceptable standard errors of estimate, especially at the optimal sampling point. The retrospective analysis of the 90 Y DOTATOC data also yielded similar results with an r2 = 0.95 and a standard error of estimate of 61 cGy. CONCLUSIONS: In situations where there is prior knowledge about the population averages of kinetic parameters, these results suggest that the single time point approach can be used to estimate the total integrated activity and dose with sufficient accuracy to manage radionuclide therapy. This will make personalized dosimetry much easier to perform and more available to the community.
Authors: Michael Ljungberg; Anna Celler; Mark W Konijnenberg; Keith F Eckerman; Yuni K Dewaraja; Katarina Sjögreen-Gleisner; Wesley E Bolch; A Bertrand Brill; Frederic Fahey; Darrell R Fisher; Robert Hobbs; Roger W Howell; Ruby F Meredith; George Sgouros; Pat Zanzonico; Klaus Bacher; Carlo Chiesa; Glenn Flux; Michael Lassmann; Lidia Strigari; Stephan Walrand Journal: J Nucl Med Date: 2015-10-15 Impact factor: 10.057
Authors: Heribert Hänscheid; Constantin Lapa; Andreas K Buck; Michael Lassmann; Rudolf A Werner Journal: J Nucl Med Date: 2017-06-06 Impact factor: 10.057
Authors: Yusuf Menda; Mark T Madsen; Thomas M O'Dorisio; John J Sunderland; G Leonard Watkins; Joseph S Dillon; Sarah L Mott; Michael K Schultz; Gideon K D Zamba; David L Bushnell; M Sue O'Dorisio Journal: J Nucl Med Date: 2018-03-09 Impact factor: 10.057
Authors: Youngho Seo; Yoonsuk Huh; Shih-Ying Huang; J Miguel Hernandez-Pampaloni; Randall A Hawkins; W Clay Gustafson; Kieuhoa T Vo; Katherine K Matthay Journal: Med Phys Date: 2019-03-12 Impact factor: 4.071
Authors: Clemens Kratochwil; Wolfgang Peter Fendler; Matthias Eiber; Richard Baum; Murat Fani Bozkurt; Johannes Czernin; Roberto C Delgado Bolton; Samer Ezziddin; Flavio Forrer; Rodney J Hicks; Thomas A Hope; Levant Kabasakal; Mark Konijnenberg; Klaus Kopka; Michael Lassmann; Felix M Mottaghy; Wim Oyen; Kambiz Rahbar; Heiko Schöder; Irene Virgolini; Hans-Jürgen Wester; Lisa Bodei; Stefano Fanti; Uwe Haberkorn; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-22 Impact factor: 9.236
Authors: Emilie Roncali; Jacek Capala; Stanley H Benedict; Gamal Akabani; Bryan Bednarz; Vikram Bhadrasain; Wesley E Bolch; Jeffrey C Buchsbaum; Norman C Coleman; Yuni K Dewaraja; Eric Frey; Michael Ghaly; Joseph Grudzinski; Robert F Hobbs; Roger W Howell; John L Humm; Charles A Kunos; Steve Larson; Frank I Lin; Mark Madsen; Saed Mirzadeh; David Morse; Daniel Pryma; George Sgouros; Sara St James; Richard L Wahl; Ying Xiao; Pat Zanzonico; Katherine Zukotynski Journal: J Nucl Med Date: 2020-12-04 Impact factor: 10.057